Idorsia Pharmaceuticals US Revenue and Competitors

Radnor, PA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Idorsia Pharmaceuticals US's estimated annual revenue is currently $29.7M per year.(i)
  • Idorsia Pharmaceuticals US's estimated revenue per employee is $472,190

Employee Data

  • Idorsia Pharmaceuticals US has 63 Employees.(i)
  • Idorsia Pharmaceuticals US grew their employee count by -47% last year.

Idorsia Pharmaceuticals US's People

NameTitleEmail/Phone
1
General Counsel, VP, Head Legal, USReveal Email/Phone
2
VP, Head Compliance, USReveal Email/Phone
3
Head US Supply chain and Senior DirectorReveal Email/Phone
4
VP, Head US Human ResourcesReveal Email/Phone
5
VP, Head US MarketingReveal Email/Phone
6
VP, US General Counsel, Head LegalReveal Email/Phone
7
VP, Head US Drug Regulatory AffairsReveal Email/Phone
8
VP, Head US ComplianceReveal Email/Phone
9
VP, Head US Finance and InfrastructuresReveal Email/Phone
10
Director, Compensation & BenefitsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M1928%N/AN/A
#2
$81.8M3463%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M178-3%N/AN/A
#6
$13.1M50-7%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M68-4%N/AN/A
#9
$67.9M40230%N/AN/A
#10
$14.9M51-16%N/AN/A
Add Company

What Is Idorsia Pharmaceuticals US?

At Idorsia US, we are bringing innovative medicines from bench to bedside. With commercial operations based outside of Philadelphia, PA, our goal is to build the commercial footprint that will deliver Idorsia’s deep pipeline of products from its R&D engine to the US market – with the potential to change the lives of many patients. For questions, please consult our channel guidelines: https://bit.ly/3k78NQr

keywords:N/A

N/A

Total Funding

63

Number of Employees

$29.7M

Revenue (est)

-47%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.7M6743%N/A
#2
N/A10417%N/A
#3
$24.4M11152%N/A
#4
$16.8M12014%$58.7M
#5
$17.2M123-3%N/A